Gastrointestinal Stromal Tumors Diagnosis and Treatment

Gastrointestinal Stromal Tumor (GIST) - Pipeline Review H1 2016 Telephone: +1 (800) 910-6452 Mail at: sales@researchbeam.com

Report Overview ‘Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H1 2016’, provides an overview of the Gastrointestinal Stromal Tumor (GIST) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Gastrointestinal Stromal Tumor (GIST), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Gastrointestinal Stromal Tumor (GIST) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Strategic Focus Report @ http://www.researchbeam.com/gastrointestinal-stromal-tumor-gist-pipelinereview-h1-2016-market

Report Overview Scope - The report provides a snapshot of the global therapeutic landscape of Gastrointestinal Stromal Tumor (GIST) - The report reviews pipeline therapeutics for Gastrointestinal Stromal Tumor (GIST) by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages -

The report assesses Gastrointestinal Stromal Tumor (GIST) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

Reasons to buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Gastrointestinal Stromal Tumor (GIST) - Devise corrective measures for pipeline projects by understanding Gastrointestinal Stromal Tumor (GIST) pipeline depth and focus of Indication therapeutics

Table of Contents Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Gastrointestinal Stromal Tumor (GIST) Overview 10 Therapeutics Development 11 Pipeline Products for Gastrointestinal Stromal Tumor (GIST) - Overview 11 Pipeline Products for Gastrointestinal Stromal Tumor (GIST) - Comparative Analysis 12 Gastrointestinal Stromal Tumor (GIST) - Therapeutics under Development by Companies 13 Gastrointestinal Stromal Tumor (GIST) - Therapeutics under Investigation by Universities/Institutes 15 Gastrointestinal Stromal Tumor (GIST) - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 Gastrointestinal Stromal Tumor (GIST) - Products under Development by Companies 19 Gastrointestinal Stromal Tumor (GIST) - Products under Investigation by Universities/Institutes 21 Gastrointestinal Stromal Tumor (GIST) - Companies Involved in Therapeutics Development 22 Advenchen Laboratories, LLC 23 Ariad Pharmaceuticals, Inc. 24 Arog Pharmaceuticals, Inc. 25 Array BioPharma Inc. 26 Astex Pharmaceuticals, Inc. 27

Table of Contents Blueprint Medicines Corporation 28 Boston Biomedical, Inc. 29 Calithera Biosciences, Inc. 30 Chipscreen Biosciences Ltd 31 Deciphera Pharmaceuticals, LLC 32 F. Hoffmann-La Roche Ltd. 33 Horizon Pharma Plc 34 Immunicum AB 35 Jiangsu Hengrui Medicine Co., Ltd. 36 Kolltan Pharmaceuticals, Inc. 37 Natco Pharma Limited 38 Nerviano Medical Sciences S.r.l. 39 Novartis AG 40 Omeros Corporation 41 Plexxikon Inc. 42 TG Therapeutics, Inc. 43 Threshold Pharmaceuticals, Inc. 44 Gastrointestinal Stromal Tumor (GIST) - Therapeutics Assessment 45 Assessment by Monotherapy Products 45 Assessment by Combination Products 46 Assessment by Target 47 Assessment by Mechanism of Action 50 Assessment by Route of Administration 53

Report Ordering

Report Name: Gastrointestinal Stromal Tumor GIST - Pipeline Review H1 2016 Product Price User

Price

Single User

US $ 1700

Site User

US $ 4000

Global User

US $ 6000

To View Sample or Purchase Report

Contact Us

FOR MORE DETAILS Visit us at : http://www.researchbeam.com/gastrointestinal-stromal-tumor-gist-pipeline-review-h1-2016-market

Stay With Us At:

TELEPHONE: +1 (800) 910-6452 DIRECT: +1 (503) 894-6022 E-MAIL: sales@researchbeam.com

5933 NE Win Sivers Drive, #205, Portland, OR 97220 United States